v3.26.1
Segment
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Segment
The Company reports segment information in accordance with the management approach, which reflects the internal reporting utilized by the Chief Operating Decision Maker (“CODM”), the Company’s President and Chief Executive Officer. Based on the information used by the CODM to allocate resources and assess the Company’s performance, the Company has determined it operates in one segment. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. Prior period segment information has been recast to reflect the manner in which financial information is currently reviewed by the CODM to allocate resources and assess performance, conforming to the current period presentation.
The CODM evaluates the performance of the Company’s sole reportable segment based on net loss that also is reported on the condensed consolidated statements of operations and comprehensive loss as net loss. The table below
details the Company’s segment net loss, significant expenses, and other segment items (in thousands). The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.
Three Months Ended March 31,
20262025
Revenue$2 $7 
Less:
Technical operations12,394 17,895 
Clinical development12,643 8,674 
Support functions5,638 8,455 
Lease costs3,709 4,446 
Operations management2,727 4,984 
Research activities2,410 3,530 
Other segment items(1)
(15,366)4,218 
Net loss$24,153 $52,195 
1.Includes stock-based compensation, depreciation, other operating income, net, interest income, net, and other income, net. For the three months ended March 31, 2026, includes a $17.6 million gain associated with the settlement of the SPA put/call.
Total expenditures for additions to the Company’s property and equipment, net were approximately $0.3 million for both the three months ended March 31, 2026 and 2025, respectively.